SCHEMBL2138759

SCHEMBL2138759

CN1C=CC(=O)[N]C1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21274286 0.67
SCHEMBL18300609 0.63
SCHEMBL13407 0.61
SCHEMBL5503560 0.57
SCHEMBL15264019 0.56
SCHEMBL17664976 0.56 GSK3A (0.33)
SCHEMBL36966 0.56
SCHEMBL11986877 0.55
SCHEMBL35261 0.55
SCHEMBL18976528 0.54 GSK3A (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150362-A1 Substituted Pyrrolotriazines MOLECURE S.A. (PL) 2024-05-09 US claimed
WO-2024042494-A1 SUBSTITUTED PYRROLOTRIAZINES MOLECURE SA (PL) 2024-02-29 WO claimed
US-20060211713-A1 Compounds having selective hydrolytic potentials CELL THERAPEUTICS, INC. 2006-09-21 US claimed
US-7053096-B2 Compounds having selective hydrolytic potentials CELL THERAPEUTICS INC. (US) 2006-05-30 US claimed
US-20040229836-A1 Compounds having selective hydrolytic potentials CELL THERAPEUTICS, INC. 2004-11-18 US claimed
US-6780865-B1 SUBSTITUTED CHIRAL XANTHINE COMPOUND, STABILITY IN ADVERSE CHEMICAL AND DYNAMIC BIOLOGIC ENVIRONMENTS CELL THERAPEUTICS, INC. 2004-08-24 US claimed
US-20030216414-A1 Method for preventing tissue injury from hypoxia CELL THERAPEUTICS,INC. 2003-11-20 US claimed
US-6638938-B1 By tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic CELL THERAPEUTICS, INC. 2003-10-28 US claimed
US-20020052511-A1 Process for the preparation of matrix metalloproteinase inhibitors BAILEY ANNE E (US) 2002-05-02 US claimed
US-20020019539-A1 Process for the preparation of matrix metalloproteinase inhibitors ABBOTT LABORATORIES 2002-02-14 US claimed
US-5641783-A ANTIINFLAMMATORY OR IMMUNOSUPPRESSIVE AGENTS CELL THERAPEUTICS, INC. (US) 1997-06-24 US claimed
EP-0739203-A1 METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF CELL THERAPEUTICS, INC. (US) 1996-10-30 EP claimed
EP-0728003-A1 METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA CELL THERAPEUTICS, INC. (US) 1996-08-28 EP claimed
EP-0728135-A1 UREA DERIVATIVES GLAXO WELLCOME S.p.A. (IT) 1996-08-28 EP claimed
EP-0676958-A1 METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION CELL THERAPEUTICS, INC. (US) 1995-10-18 EP claimed
WO-1995019171-A1 METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF CELL THERAPEUTICS, INC. (US) 1995-07-20 WO claimed
WO-1995013808-A1 METHOD FOR SELECTIVELY INHIBITING IL-2 SIGNAL TRANSDUCTION CELL THERAPEUTICS, INC. (US) 1995-05-26 WO claimed
WO-1995013075-A1 METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA CELL THERAPEUTICS, INC. (US) 1995-05-18 WO claimed
WO-1995013278-A1 UREA DERIVATIVES GLAXO WELLCOME S.P.A. (IT) 1995-05-18 WO claimed
WO-1995012396-A1 METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION CELL THERAPEUTICS, INC. (US) 1995-05-11 WO claimed